You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 5, 2024

~ Buy the SPRAVATO (esketamine hydrochloride) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR SPRAVATO


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for SPRAVATO

Trial ID Title Status Sponsor Phase Start Date Summary
NCT05268497 ↗ A Study to Assess Feasibility of Using Clinician-directed and Digital Application Supported Cognitive Behavior Therapy (CBT) in Conjunction With Esketamine in Participants With Treatment-resistant Depression Not yet recruiting Janssen Research & Development, LLC Phase 1 2022-03-14 The purpose of this study is to explore feasibility of combining clinician-directed cognitive behavioral therapy (CBT) supplemented with the Mindset app with esketamine therapy in participants with Treatment-resistant Depression.
NCT05323019 ↗ Repeated Intranasal Esketamine Plus Almond Therapy in Patients With Treatment Resistant Depression Not yet recruiting Zylorion Health Phase 2 2022-05-01 To examine the efficacy of Almond Therapy compared to Treatment as Usual when used in addition to an approved version of intranasal esketamine.
NCT05554627 ↗ VA Aripiprazole vs Esketamine for Treatment Resistant Depression Not yet recruiting VA Office of Research and Development Phase 4 2023-03-01 This is an open-label, parallel-group, randomized clinical trial of up to 6 months treatment of adjunctive intranasal (IN) esketamine (ESK) vs. adjunctive aripiprazole (ARI) in Veterans with unipolar Treatment Resistant Depression (TRD). This study will assess the efficacy, safety, and acceptability of adjunctive IN ESK in comparison to ARI, one of the best studied and most widely used adjunctive therapies for TRD. The primary hypothesis is that participants receiving adjunctive IN ESK will be significantly more likely to achieve remission after six weeks of treatment as compared to those who receive adjunctive ARI. Depressive symptoms will be assessed by central raters (CR), blinded to treatment assignment, using the clinician rated version of the Quick Inventory of Depressive Symptomatology (QIDS-C16), a well-validated tool that is commonly used and is easily translated across other depression inventory scales. The study is powered to detect an absolute difference in remission rates of 10%, or larger, at 6 weeks. Additional outcomes of interest include symptom reduction across 6 months of randomized therapy, side effects and other tolerability indices, attrition rates and measures of quality of life and cost-effectiveness.
NCT06103760 ↗ Positioning of Esketamine Treatment in the Real-world Management of Depression Recruiting Janssen-Cilag Pty Ltd Phase 4 2023-10-31 The goal of this naturalistic, open label, single arm intervention study is to investigate the effects of Esketamine in treating depression.The main aims to answer are: - to investigate whether Esketamine is effective when added to ongoing antidepressant treatment - to identify patient characteristics that will determine a therapeutic response to Esketamine in real-world practice Participants will: - attend the clinic for supervised self-administration of intranasal Esketamine treatment - be observed for 2 hours following Esketamine administration including blood pressure monitoring - be asked to complete a battery of questionnaires - be reimbursed for travel expenses
NCT06103760 ↗ Positioning of Esketamine Treatment in the Real-world Management of Depression Recruiting Royal North Shore Hospital Phase 4 2023-10-31 The goal of this naturalistic, open label, single arm intervention study is to investigate the effects of Esketamine in treating depression.The main aims to answer are: - to investigate whether Esketamine is effective when added to ongoing antidepressant treatment - to identify patient characteristics that will determine a therapeutic response to Esketamine in real-world practice Participants will: - attend the clinic for supervised self-administration of intranasal Esketamine treatment - be observed for 2 hours following Esketamine administration including blood pressure monitoring - be asked to complete a battery of questionnaires - be reimbursed for travel expenses
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for SPRAVATO

Condition Name

Condition Name for SPRAVATO
Intervention Trials
Depression 1
Depressive Disorder, Major 1
Major Depressive Disorder 1
Treatment Resistant Major Depressive Disorder 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for SPRAVATO
Intervention Trials
Depressive Disorder 4
Depression 3
Depressive Disorder, Major 3
Depressive Disorder, Treatment-Resistant 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for SPRAVATO

Trials by Country

Trials by Country for SPRAVATO
Location Trials
United States 25
Australia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for SPRAVATO
Location Trials
Ohio 2
Illinois 2
Connecticut 2
Indiana 1
Georgia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for SPRAVATO

Clinical Trial Phase

Clinical Trial Phase for SPRAVATO
Clinical Trial Phase Trials
Phase 4 2
Phase 2 1
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for SPRAVATO
Clinical Trial Phase Trials
Not yet recruiting 3
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for SPRAVATO

Sponsor Name

Sponsor Name for SPRAVATO
Sponsor Trials
Janssen Research & Development, LLC 1
Zylorion Health 1
VA Office of Research and Development 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for SPRAVATO
Sponsor Trials
Industry 3
U.S. Fed 1
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.